We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+10.56%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.98B
AUM Growth
+$247M
Cap. Flow
+$143M
Cap. Flow %
7.22%
Top 10 Hldgs %
27.18%
Holding
159
New
18
Increased
48
Reduced
15
Closed
10

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$33.7M
2
UNH icon
UnitedHealth
UNH
+$26.1M
3
AET
Aetna Inc
AET
+$23.7M
4
MRSN
Mersana Therapeutics
MRSN
+$21.1M
5
TMO icon
Thermo Fisher Scientific
TMO
+$18.5M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$27.3M
2
SHPG
Shire pic
SHPG
+$24.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$21.9M
4
AMGN icon
Amgen
AMGN
+$16.1M
5
PTHN
Patheon N.V.
PTHN
+$10.5M

Sector Composition

Rank Sector Weight
1 Healthcare 79.63%
2 Financials 3.78%
3 Consumer Discretionary 1.13%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BAX icon
51
Baxter International
BAX
$14.1B
$13.9M 0.7%
+230,000
New +$13.1M
EHC icon
52
Encompass Health
EHC
$11B
$12.8M 0.65%
333,105
– –
ACRS icon
53
Aclaris Therapeutics
ACRS
$888M
$11.9M 0.6%
440,000
-235,000
-35% -$6.39M
ONC
54
BeOne Medicines Ltd
ONC
$36.4B
$11.9M 0.6%
265,000
– –
NVTA
55
DELISTED
Invitae Corporation
NVTA
$11.5M 0.58%
1,200,000
– –
SRGA
56
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$11.4M 0.58%
65,000
+3,000
+5% +$427K
BOLD
57
DELISTED
Audentes Therapeutics, Inc
BOLD
$11.4M 0.58%
595,200
+95,200
+19% +$1.52M
BMRN icon
58
BioMarin Pharmaceuticals
BMRN
$11.7B
$11.4M 0.57%
125,000
– –
DERM
59
DELISTED
Dermira, Inc.
DERM
$11.3M 0.57%
387,600
– –
RARX
60
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$11.2M 0.57%
600,000
-188,959
-24% -$4.26M
ARDX icon
61
Ardelyx
ARDX
$1.24B
$10.2M 0.52%
2,000,000
– –
RARE icon
62
Ultragenyx Pharmaceutical
RARE
$2.46B
$9.97M 0.5%
160,500
+750
+0.5% +$45.2K
CHRS icon
63
Coherus Oncology
CHRS
$224M
$9.96M 0.5%
693,900
+18,900
+3% +$364K
XENT
64
DELISTED
Intersect ENT, Inc
XENT
$9.64M 0.49%
345,000
– –
KYNB
65
Kyntra Bio
KYNB
$28.3M
$9.04M 0.46%
11,200
+1,600
+17% +$1.11M
ASND icon
66
Ascendis Pharma A/S
ASND
$16B
$9.02M 0.46%
325,000
– –
MDGL icon
67
Madrigal Pharmaceuticals
MDGL
$11.9B
$8.78M 0.44%
540,000
+315,000
+140% +$4.92M
CLSD
68
DELISTED
Clearside Biomedical
CLSD
$8.52M 0.43%
62,333
– –
TXMD icon
69
TherapeuticsMD
TXMD
$24M
$8.43M 0.43%
32,000
– –
ALNY icon
70
Alnylam Pharmaceuticals
ALNY
$30.6B
$8.38M 0.42%
+105,000
New +$6.71M
CO
71
DELISTED
Global Cord Blood Corporation
CO
$8.34M 0.42%
880,000
– –
ASMB icon
72
Assembly Biosciences
ASMB
$526M
$8.05M 0.41%
32,500
– –
INSM icon
73
Insmed
INSM
$21.5B
$8.03M 0.41%
468,000
– –
ACHN
74
DELISTED
Achillion Pharmaceuticals
ACHN
$7.92M 0.4%
1,725,000
+225,000
+15% +$904K
PTLA
75
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$7.86M 0.4%
+140,000
New +$5.61M
1 2
3
4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

Rock Springs Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Rock Springs Capital Management held 159 positions worth $1.98B, up 14% from $1.73B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management deployed $143M of net new capital in Q2 2017, opening 18 new positions and adding to 48 existing holdings. Its largest new stake was Medtronic: 400,000 shares worth $35.5M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 82% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $21.9M trimmed.

  • Rock Springs Capital Management's largest Q2 2017 buy was Medtronic: 400,000 shares worth $35.5M.
  • Rock Springs Capital Management added most to UnitedHealth in Q2 2017, an estimated $26.1M increase.
  • Rock Springs Capital Management's biggest Q2 2017 reduction was Bristol-Myers Squibb, cutting an estimated $21.9M.
  • Rock Springs Capital Management fully exited Eli Lilly in Q2 2017, selling an estimated $27.3M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $1.98B portfolio in Q2 2017.
  • Rock Springs Capital Management opened 18 new positions and closed 10 in Q2 2017.
  • Rock Springs Capital Management's portfolio value rose 14% quarter-over-quarter to $1.98B.

Based on Rock Springs Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.